Wells Fargo
CGON icon

Wells Fargo’s CG Oncology CGON Stock Holding History

Wells Fargo’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.42M Buy
76,220
+51,620
+210% +$3.37M ﹤0.01% 2766
2026
Q1 		$1.66M Sell
24,600
-37,952
-61% -$2.15M ﹤0.01% 3404
2025
Q4 		$2.6M Buy
62,552
+26,297
+73% +$1.09M ﹤0.01% 3231
2025
Q3 		$1.46M Buy
36,255
+1,600
+5% +$46.5K ﹤0.01% 3545
2025
Q2 		$901K Buy
34,655
+508
+1% +$12.2K ﹤0.01% 3758
2025
Q1 		$836K Buy
34,147
+5,913
+21% +$166K ﹤0.01% 3767
2024
Q4 		$810K Buy
28,234
+8,803
+45% +$301K ﹤0.01% 3858
2024
Q3 		$733K Buy
19,431
+8,885
+84% +$311K ﹤0.01% 3748
2024
Q2 		$333K Buy
10,546
+923
+10% +$32K ﹤0.01% 4174
2024
Q1 		$422K Buy
+9,623
New +$393K ﹤0.01% 4001

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wells Fargo's CGON Position: Q2 2026 in Review

Wells Fargo increased its CG Oncology (CGON) stake by 210% in Q2 2026, buying an estimated $3.37M and bringing the position to 76,220 shares worth $5.42M. The position accounts for ﹤0.01% of the portfolio, ranked #2766.

Wells Fargo first reported a position in CGON in Q1 2024 and has held it in 10 quarters since. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Wells Fargo held 76,220 shares of CG Oncology worth $5.42M as of Q2 2026.
  • Wells Fargo bought 51,620 CG Oncology shares in Q2 2026, an estimated $3.37M.
  • CG Oncology made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #2766 holding.
  • Wells Fargo first reported a position in CG Oncology in Q1 2024 and has held it in 10 quarters since.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.